Last update :
18/04/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Antibiotic   Ceftazidime  
Injection
Eye-drops
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Bactazid Chile
Bagram Mexico
Biotum Poland
Cefatril Brazil
Cefidime Egypt
Cefortam Portugal
Ceftamil Romania
Ceftim Italy
Ceftimira Chile
Ceftram Ecuador
Efadima Chile
Fortam Spain, Switzerland
Fortaz Brazil, Canada, United States of America
Fortum Argentina, Australia, Austria, Chile, Colombia, Denmark, Egypt, France, Germany, Great Britain, Iceland, Ireland, Morocco, Netherlands, New Zealand, Norway, Peru, Poland, Romania, Sweden, Tunisia, Turkey, United Arab Emirates, Venezuela
Ftazidime Greece
Glazidim Belgium, Finland, Italy, Luxembourg
Iesetum Turkey
Intracef Brazil
Kefadim Belgium, Brazil, Egypt, Great Britain, Morocco, Saudi Arabia
Kefamin Spain
Kefazim Austria
Kefzim Republic of South Africa
Lorazidime Iran
Negacef Saudi Arabia, United Arab Emirates
Novocral Greece
Panzid Italy
Parzidime Saudi Arabia
Pluseptic Argentina
Sigmazidim Egypt
Solvetan Denmark, Greece
Spectrum Italy
Starcef Italy
Sturdizime Mexico
Sumizidima Colombia
Tazicef United States of America
Zadolina Mexico
Zidacef Saudi Arabia
Zidime Morocco, Saudi Arabia, United Arab Emirates
Zidimox Portugal
Stability of mixtures   Injection   Stability of mixtures : Ceftazidime     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Not specified 10 mg/ml
Injection   Ceftazidime   
Injection   Ranitidine hydrochloride 0,5 mg/ml
23°C
4 Hour
Light 360
Level of evidence B
Glass NaCl 0,9% or Glucose 5% 40 mg/ml
Injection   Ceftazidime   
Injection   Aminophylline 2 mg/ml
25°C
2 Hour
Not specified 900
Glass Sodium chloride 0,9% 8,35 mg/ml
Injection   Ceftazidime   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Light 57
Level of evidence A+
Glass Sodium chloride 0,9% 10 mg/ml
Injection   Ceftazidime   
Injection   Ranitidine hydrochloride 0,5 mg/ml
22°C-23°C
4 Hour
Light 360
Level of evidence B
Glass Sodium chloride 0,9% 20 mg/ml
Injection   Ceftazidime   
Injection   Clindamycin phosphate 9 mg/ml
25°C
48 Hour
Light 432
Level of evidence D
Glass Glucose 5% 20 & 100 mg/ml
Injection   Ceftazidime   
Injection   Tacrolimus 5 & 20 µg/ml
23°C-25°C
4 Hour
Light 814
Level of evidence A
Glass Glucose 5% 5 mg/ml
Injection   Ceftazidime   
Injection   Tenoxicam 0,2 mg/ml
25°C
96 Hour
Protect from light 1943
Glass Glucose 5% 20 mg/ml
Injection   Ceftazidime   
Injection   Clindamycin phosphate 9 mg/ml
25°C
24 Hour
Light 432
Level of evidence D
Glass Glucose 5% 5 mg/ml
Injection   Ceftazidime   
Injection   Filgrastim 40 µg/ml
25°C
4 Hour
Not specified 104
Level of evidence B
Glass None 10 mg/ml
Injection   Ceftazidime   
Injection   Ofloxacin 2 mg/ml
25°C
48 Hour
Not specified 889
Level of evidence D
Polyvinyl chloride Glucose 5% 5 mg/ml
Injection   Ceftazidime   
Injection   Tenoxicam 0,2 mg/ml
25°C
72 Hour
Protect from light 1943
Polyvinyl chloride Glucose 5% 5 mg/ml
Injection   Ceftazidime   
Injection   Tenoxicam 0,2 mg/ml
4°C
96 Hour
Protect from light 1943
Polyvinyl chloride None 10 mg/ml
Injection   Ceftazidime   
Injection   Metronidazole 5 mg/ml
8°C
72 Hour
Not specified 282
Level of evidence A
Polyvinyl chloride Dianéal® PD2 4.25% glucose (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Vancomycin hydrochloride 1 mg/ml
24°C
24 Hour
1416
Level of evidence D
Polyvinyl chloride Dianéal® PD2 4.25% glucose (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Vancomycin hydrochloride 1 mg/ml
37°C
12 Hour
Light 1416
Level of evidence D
Polyvinyl chloride Dianéal® PD2 4.25% glucose (Baxter) 0.125 mg/ml
Injection   Ceftazidime   
Injection   Heparin sodium 0.5 UI/ml
37°C
12 Hour
Not specified 4056
Level of evidence B+
Polyvinyl chloride Dianéal® PD2 4.25% glucose (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Vancomycin hydrochloride 1 mg/ml
4°C
24 Hour
Light 1416
Level of evidence D
Polyvinyl chloride Dianéal® PD2 4.25% glucose (Baxter) 0.125 mg/ml
Injection   Ceftazidime   
Injection   Heparin sodium 0.5 UI/ml
4°C
120 Hour
Not specified 4056
Level of evidence B+
Polyvinyl chloride Dianéal® PD2 1.5% glucose (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Vancomycin hydrochloride 1 mg/ml
24°C
24 Hour
1416
Level of evidence D
Polyvinyl chloride Dianéal® PD2 1.5% glucose (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Vancomycin hydrochloride 1 mg/ml
37°C
12 Hour
1416
Level of evidence D
Polyvinyl chloride Dianéal® PD2 1.5% glucose (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Vancomycin hydrochloride 1 mg/ml
4°C
24 Hour
1416
Level of evidence D
Polyvinyl chloride Dianéal® PD2 2.5% glucose (Baxter) 0,125 mg/ml
Injection   Ceftazidime   
Injection   Tobramycin sulfate 0,008 mg/ml
24°C
16 Hour
Not specified 2369
Level of evidence B
Polyvinyl chloride Dianéal® PD2 2.5% glucose (Baxter) 0,125 mg/ml
Injection   Ceftazidime   
Injection   Tobramycin sulfate 0,008 mg/ml
37°C
8 Hour
Not specified 2369
Level of evidence B
Polyvinyl chloride Dianéal® PD2 2.5% glucose (Baxter) 0.125 mg/ml
Injection   Ceftazidime   
Injection   Heparin sodium 0.5 UI/ml
37°C
12 Hour
Not specified 4056
Level of evidence B+
Polyvinyl chloride Dianéal® PD2 2.5% glucose (Baxter) 0.125 mg/ml
Injection   Ceftazidime   
Injection   Heparin sodium 0.5 UI/ml
4°C
120 Hour
Not specified 4056
Level of evidence B+
Polyvinyl chloride Extraneal® (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Cefazolin sodium 0,5 mg/ml
25°C
2 Day
Protect from light 3888
Level of evidence D
Polyvinyl chloride Extraneal® (Baxter) 0,125 mg/ml
Injection   Ceftazidime   
Injection   Cefazolin sodium 0,125 mg/ml
25°C
24 Hour
Not specified 3651
Level of evidence C
Polyvinyl chloride Extraneal® (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Cefazolin sodium 0,5 mg/ml
37°C
24 Hour
Protect from light 3888
Level of evidence D
Polyvinyl chloride Extraneal® (Baxter) 0.125 mg/ml
Injection   Ceftazidime   
Injection   Heparin sodium 0.5 UI/ml
37°C
12 Hour
Not specified 4056
Level of evidence B+
Polyvinyl chloride Extraneal® (Baxter) 0,125 mg/ml
Injection   Ceftazidime   
Injection   Cefazolin sodium 0,125 mg/ml
37°C
24 Hour
Not specified 3651
Level of evidence C
Polyvinyl chloride Extraneal® (Baxter) 0,125 mg/ml
Injection   Ceftazidime   
Injection   Cefazolin sodium 0,125 mg/ml
4°C
7 Day
Protect from light 3651
Level of evidence C
Polyvinyl chloride Extraneal® (Baxter) 0,5 mg/ml
Injection   Ceftazidime   
Injection   Cefazolin sodium 0,5 mg/ml
4°C
14 Day
Protect from light 3888
Level of evidence D
Polyvinyl chloride Extraneal® (Baxter) 0.125 mg/ml
Injection   Ceftazidime   
Injection   Heparin sodium 0.5 UI/ml
4°C
120 Hour
Not specified 4056
Level of evidence B+
Polyolefine None 20 mg/ml
Injection   Ceftazidime   
Injection   Linezolid 2 mg/ml
23°C
24 Hour
Protect from light 1659
Level of evidence A+
Polyolefine None 20 mg/ml
Injection   Ceftazidime   
Injection   Linezolid 2 mg/ml
4°C
7 Day
Protect from light 1659
Level of evidence A+
Not specified Sodium chloride 0,9% 16,7 mg/ml
Injection   Ceftazidime   
Injection   Daptomycin 16,7 mg/ml
22°C-28°C
2 Hour
Not specified 1937
Level of evidence C+
  Mentions Légales